Amicus Therapeutics (FRA:AM6) EV-to-Revenue : 8.09 (As of May. 07, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Amicus Therapeutics's enterprise value is €2,994.5 Mil. Amicus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €370.3 Mil. Therefore, Amicus Therapeutics's EV-to-Revenue for today is 8.09.

The historical rank and industry rank for Amicus Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:AM6' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.26 Med: 23.03 Max: 4964.07
Current: 8.07

During the past 13 years, the highest EV-to-Revenue of Amicus Therapeutics was 4964.07. The lowest was 2.26. And the median was 23.03.

FRA:AM6's EV-to-Revenue is ranked better than
50.39% of 1034 companies
in the Biotechnology industry
Industry Median: 8.205 vs FRA:AM6: 8.07

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-07), Amicus Therapeutics's stock price is €9.55. Amicus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €1.25. Therefore, Amicus Therapeutics's PS Ratio for today is 7.62.

Amicus Therapeutics EV-to-Revenue Historical Data

The historical data trend for Amicus Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics EV-to-Revenue Chart

Amicus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

12.32

23.03

10.41

10.91

10.83

Amicus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															10.91	9.88	10.81	9.96	10.83

Competitive Comparison of Amicus Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Amicus Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's EV-to-Revenue falls into.

Amicus Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Amicus Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2994.490	/	370.312
	=	8.09

Amicus Therapeutics's current Enterprise Value is €2,994.5 Mil.
Amicus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €370.3 Mil.

Amicus Therapeutics (FRA:AM6) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Amicus Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	9.55	/	1.254
	=	7.62

Amicus Therapeutics's share price for today is €9.55.
Amicus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.25.

Amicus Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics (FRA:AM6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (FRA:AM6) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

FOLD:USA AM6:Germany

Address

3675 Market Street, Philadelphia, PA, USA, 19104

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics (FRA:AM6) Headlines

No Headlines